Drug Discovery Services Market - All You Need to Know About Emerging Innovations


Posted March 22, 2022 by mmvaidya

The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
 
According to the new market research report, "Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) - Global Forecast to 2026" The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026.

Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129

Global Industry Growth Boosting Factors:

Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market. On the other hand, stringent regulations governing drug discovery and animal usage are expected to restrain market growth to a certain extent. The shortage of skilled professionals poses a challenge for drug discovery service providers.

Overview:

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

DRIVER: Growing R&D expenditure in the Pharma and Biopharma companies

Most pharmaceutical, biopharmaceutical, and medical device companies invest heavily in developing novel drugs and devices. The pharmaceutical industry is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns in the longer term and through collaborative R&D efforts. According to the EvaluatePharma report, worldwide pharmaceutical R&D spending was valued at USD 137 billion in 2012; this increased to USD 198 billion in 2020. As a result of the COVID-19 outbreak, the global pharma R&D growth rate dropped to 0.1% in 2020. According to the report, this R&D spend is expected to grow steadily between 2020 and 2026 at a CAGR of 4.2% to reach USD 254.0 billion, slower than the historical CAGR of 4.7% between 2012 and 2020.

Request Sample [email protected] https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129

RESTRAINT: Stringent regulations governing drug discovery and animal usage

Securing safety and efficacy is the prime focus of regulatory authorities during drug approval. Although these approaches help ensure the quality of the products launched in the market, they substantially increase the cost of drug development and the final product. In price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Apart from this, various legislations that ensure the quality of the product (such as GMP) often increase manufacturing costs.

OPPORTUNITY: Growth in drugs and biologics market despite Covid-19 Pandemic

Despite the ongoing COVID-19 pandemic, 2020 has been the second-best year for the pharmaceutical industry regarding the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 comprised 40 new chemical entities and 13 biologics (of which ten were monoclonal antibodies, two were antibody-drug conjugates, three were peptides, and two, oligonucleotides). The FDA authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010.

CHALLENGE: Shortage of Skilled Personnel

The global pharmaceutical, biotechnology, and medical device R&D outsourcing industry is constantly evolving. Professionals must keep pace with the continuing changes in pharmaceutical R&D technologies and methodologies, provide quality services, and comply with good laboratory practices. CROs face challenges in attracting and retaining highly skilled professionals as they compete with pharmaceutical and biotechnology companies and academic and research institutions for qualified and experienced scientists.

To compete effectively, companies have to offer higher compensations and other benefits; this may affect the finances and results of operations of players, especially small-scale analytical testing providers. This shortage of skilled professionals may hamper the adoption of new technologies and methodologies and inhibit the growth of the drug discovery services market in the coming years.

Speak to Analyst for More Detailed [email protected] https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=138732129
-- END ---
Contact Email [email protected]
Issued By Makarand Vaidya
Country United States
Categories Industry , Medical , News
Tags drug discovery services , drug discovery services market
Last Updated March 22, 2022